Systemic sclerosis-associated pulmonary arterial hypertension

Chest

Volumn 144, Issue 4, 2013, Pages 1346-1356

  Chaisson, Neal F ^a   Hassoun, Paul M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; AMBRISENTAN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; IMATINIB; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; RITUXIMAB; SILDENAFIL; TADALAFIL; TREPROSTINIL;

ARTICLE; AUTOIMMUNE DISEASE; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR RESPONSE; CAUSE OF DEATH; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); DELAYED DIAGNOSIS; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; EARLY DIAGNOSIS; EARLY INTERVENTION; EXERCISE; EXERCISE TEST; GENETIC POLYMORPHISM; HEART AFTERLOAD; HEART DISEASE; HEMODYNAMICS; HIGH RISK POPULATION; HUMAN; INJECTION SITE IRRITATION; INTERSTITIAL LUNG DISEASE; LOW DRUG DOSE; MORTALITY; MUSCULOSKELETAL DISEASE; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN ANALYSIS; PULMONARY HYPERTENSION; PULSE OXIMETRY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RAYNAUD PHENOMENON; SYSTEMIC SCLEROSIS; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT DURATION;

EID: 84885141386     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-2396     Document Type: Article

References (96)

1. Jimenez SA, Derk CT. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med. 2004; 140 (1): 37-50.
2. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis. 2007; 66 (7): 940-944.
3. Thenappan T, Shah SJ, Rich S, Gomberg-Maitland M. A USAbased registry for pulmonary arterial hypertension: 1982-2006. Eur Respir J. 2007 ;30(6): 1103-1110.
4. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006; 173 (9): 1023-1030.
5. Fisher MR, Mathai SC, Champion HC, et al. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum. 2006; 54 (9): 3043-3050.
6. Clements PJ, Tan M, McLaughlin VV, et al; Pulmonary Arterial Hypertension Quality Enhancement Research Initiative (PAH-QuERI) Investigators. The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH. Ann Rheum Dis. 2012; 71(2): 249-252.
7. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009; 54 (suppl 1): S43-S54.
8. Mayes MD. Scleroderma epidemiology. Rheum Dis Clin North Am. 2003; 29 (2): 239-254.
9. Allcock RJ, Forrest I, Corris PA, Crook PR, Griffiths ID. A study of the prevalence of systemic sclerosis in northeast England. Rheumatology (Oxford). 2004; 43 (5): 596-602.
10. Avouac J, Airò P, Meune C, et al. Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. J Rheumatol. 2010; 37(11): 2290-2298.
11. Gaine SP, Rubin LJ. Primary pulmonary hypertension. Lancet. 1998; 352 (9129): 719-725.
12. Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010; 137 (2): 376-387.
13. Chang B, Schachna L, White B, Wigley FM, Wise RA. Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma. J Rheumatol. 2006; 33 (2): 269-274.
14. Cox SR, Walker JG, Coleman M, et al. Isolated pulmonary hypertension in scleroderma. Intern Med J. 2005; 35(1): 28-33.
15. Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum. 2003; 48 (2): 516-522.
16. Hinchcliff M, Fischer A, Schiopu E, Steen VD; PHAROS Investigators. Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): baseline characteristics and description of study population. J Rheumatol. 2011; 38 (10): 2172-2179.
17. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med. 2004; 351 (16): 1655-1665.
18. Kherbeck N, Tamby MC, Bussone G, et al. The role of inflammation and autoimmunity in the pathophysiology of pulmonary arterial hypertension. Clin Rev Allergy Immunol. 2013; 44 (1): 31-38.
19. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med. 2009; 360 (19): 1989-2003.
20. Nicolls MR, Taraseviciene-Stewart L, Rai PR, Badesch DB, Voelkel NF. Autoimmunity and pulmonary hypertension: a perspective. Eur Respir J. 2005 ;26(6): 1110-1118.
21. Riemekasten G, Philippe A, Näther M, et al. Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis. 2011; 70 (3): 530-536.
22. Negi VS, Tripathy NK, Misra R, Nityanand S. Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension. J Rheumatol. 1998; 25 (3): 462-466.
23. Bordron A, Dueymes M, Levy Y, et al. The binding of some human antiendothelial cell antibodies induces endothelial cell apoptosis. J Clin Invest. 1998; 101 (10): 2029-2035.
24. Tamby MC, Humbert M, Guilpain P et al. Antibodies to fibroblasts in idiopathic and scleroderma-associated pulmonary hypertension. Eur Respir J. 2006 ;28(4): 799-807.
25. Tamby MC, Servettaz A, Tamas N et al. IgG from patients with systemic sclerosis bind to DNA antitopoisomerase 1 in normal human fibroblasts extracts. Biologics. 2008 ;2(3): 583-591.
26. Sanchez O, Sitbon O, Jaïs X, Simonneau G, Humbert M. Immunosuppressive therapy in connective tissue diseasesassociated pulmonary arterial hypertension. Chest. 2006; 130 (1): 182-189.
27. Morse J, Barst R, Horn E, Cuervo N, Deng Z, Knowles J. Pulmonary hypertension in scleroderma spectrum of disease: lack of bone morphogenetic protein receptor 2 mutations. J Rheumatol. 2002; 29 (11): 2379-2381.
28. Austin ED, Loyd JE. Genetics and mediators in pulmonary arterial hypertension. Clin Chest Med. 2007; 28 (1): 43-57.
29. Wipff J, Kahan A, Hachulla E, et al. Association between an endoglin gene polymorphism and systemic sclerosis-related pulmonary arterial hypertension. Rheumatology (Oxford). 2007; 46 (4): 622-625.
30. Ryu JH, Krowka MJ, Pellikka PA, Swanson KL, McGoon MD. Pulmonary hypertension in patients with interstitial lung diseases. Mayo Clinic Proc. 2007; 82 (3): 342-350.
31. MacGregor AJ, Canavan R, Knight C, et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford). 2001; 40 (4): 453-459.
32. Mukerjee D, St George D, Coleiro B, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis. 2003; 62 (11): 1088-1093.
33. Mathai SC, Hummers LK, Champion HC, et al. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum. 2009; 60 (2): 569-577.
34. Le Pavec J, Girgis RE, Lechtzin N, et al. Systemic sclerosisrelated pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies. Arthritis Rheum. 2011; 63 (8): 2456-2464.
35. Boueiz A, Mathai SC, Hummers LK, Hassoun PM. Cardiac complications of systemic sclerosis: recent progress in diagnosis. Curr Opin Rheumatol. 2010; 22 (6): 696-703.
36. Thompson AE, Pope JE. A study of the frequency of pericardial and pleural effusions in scleroderma. Br J Rheumatol. 1998; 37 (12): 1320-1323.
37. de Groote P, Gressin V, Hachulla E, et al; ItinerAIR-Scleroderma Investigators. Evaluation of cardiac abnormalities by Doppler echocardiography in a large nationwide multicentric cohort of patients with systemic sclerosis. Ann Rheum Dis. 2008; 67 (1): 31-36.
38. Girgis RE, Mathai SC, Krishnan JA, Wigley FM, Hassoun PM. Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases. J Hearth Lung Transplant. 2005 ;24(10): 1626-1631.
39. Randone SB, Guiducci S, Cerinic MM. Musculoskeletal involve ment in systemic sclerosis. Best Pract Res Clin Rheumatol. 2008; 22 (2): 339-350.
40. McLaughlin VV, Archer SL, Badesch DB, et al; ACCF/AHA. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation. 2009; 119 (16): 2250-2294.
41. Mathai SC, Hassoun PM. Pulmonary arterial hypertension associated with systemic sclerosis. Expert Rev Respir Med. 2011; 5 (2): 267-279.
42. Campo A, Mathai SC, Le Pavec J, et al. Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med. 2010; 182(2): 252-260.
43. Hachulla E, de Groote P, Gressin V, et al; Itinér AIRSclérodermie Study Group. The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. Arthritis Rheum. 2009; 60 (6): 1831-1839.
44. Hachulla E, Carpentier P, Gressin V, et al; ItinérAIRSclé rodermie Study Investigators. Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinérAIR- Sclérodermie study. Rheumatology (Oxford). 2009; 48 (3): 304-308.
45. Janda S, Shahidi N, Gin K, Swiston J. Diagnostic accuracy of echocardiography for pulmonary hypertension: a systematic review and meta-analysis. Heart. 2011; 97 (8): 612-622.
46. Gailiè N, Hoeper MM, Humbert M, et al; Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC), European Respiratory Society (ERS), International Society of Heart and Lung Transplantation (ISHLT). Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2009 ;34(6): 1219-1263.
47. Mukerjee D, St George D, Knight C, et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford). 2004; 43 (4): 461-466.
48. Cavagna L, Caporali R, Klersy C, et al. Comparison of brain natriuretic peptide (BNP) and NT-proBNP in screening for pulmonary arterial hypertension in patients with systemic sclerosis. J Rheumatol. 2010; 37 (10): 2064-2070.
49. York M, Farber HW. Pulmonary hypertension: screening and evaluation in scleroderma. Curr Opin Rheumatol. 2011; 23 (6): 536-544.
50. Allanore Y, Borderie D, Avouac J, et al. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum. 2008; 58(1): 284-291.
51. Schreiber BE, Valerio CJ, Keir GJ, et al. Improving the detection of pulmonary hypertension in systemic sclerosis using pulmonary function tests. Arthritis Rheum. 2011; 63(11): 3531-3539.
52. Meune C, Avouac J, Airò P, et al. Prediction of pulmonary hypertension related to systemic sclerosis by an index based on simple clinical observations. Arthritis Rheum. 2011; 63 (9): 2790-2796.
53. McLaughlin V, Coghlan G, Denton C, et al. An evidencebased screening algorithm for pulmonary arterial hypertension in systemic sclerosis: the DETECT study [abstract]. Chest. 2012 ;142(4-MeetingAbstracts): 809A.
54. Chatterjee S. Pulmonary hypertension in systemic sclerosis. Semin Arthritis Rheum. 2011; 41 (1): 19-37.
55. Alpert MA, Pressly TA, Mukerji V, et al. Acute and longterm effects of nifedipine on pulmonary and systemic hemodynamics in patients with pulmonary hypertension associated with diffuse systemic sclerosis, the CREST syndrome and mixed connective tissue disease. Am J Cardiol. 1991; 68 (17): 1687-1691.
56. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987; 107 (2): 216-223.
57. Mininni S, Diricatti G, Vono MC, et al. Noninvasive evaluation of right ventricle systolic pressure during dynamic exercise by saline-enhanced Doppler echocardiography in progressive systemic sclerosis. Angiology. 1996; 47(5): 467-474.
58. Alkotob ML, Soltani P, Sheatt MA, et al. Reduced exercise capacity and stress-induced pulmonary hypertension in patients with scleroderma. Chest. 2006; 130 (1): 176-181.
59. Steen V, Chou M, Shanmugam V, Mathias M, Kuru T, Morrissey R. Exercise-induced pulmonary arterial hypertension in patients with systemic sclerosis. Chest. 2008; 134 (1): 146-151.
60. Kovacs G, Maier R, Aberer E, et al. Pulmonary arterial hypertension therapy may be safe and effective in patients with systemic sclerosis and borderline pulmonary artery pressure. Arthritis Rheum. 2012; 64 (4): 1257-1262.
61. Kovacs G, Berghold A, Scheidl S, Olschewski H. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J. 2009 ;34(4): 888-894.
62. Barst RJ, Rubin LJ, Long WA, et al; Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996; 334 (5): 296-301.
63. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000; 132 (6): 425-434.
64. Galiè N, Ghofrani HA, Torbicki A, et al; Sildenafil Use in Pul monary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005; 353 (20): 2148-2157.
65. Badesch DB, Hill NS, Burgess G, et al; SUPER Study Group. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol. 2007; 34 (12): 2417-2422.
66. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002; 346 (12): 896-903.
67. Galié N, Badesch D, Oudiz R, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2005; 46 (3): 529-535.
68. Avouac J, Wipff J, Kahan A, Allanore Y. Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials. Ann Rheum Dis. 2008; 67 (6): 808-814.
69. Johnson SR, Brode SK, Mielniczuk LM, Granton JT. Dual therapy in IPAH and SSc-PAH. A qualitative systematic review. Respir Med. 2012; 106 (5): 730-739.
70. National Institutes of Health Clinical Center. A 24-week randomized placebo-controlled, double-blind multi-center clinical trial evaluating the efficacy and safety of oral qti571 as an add-on therapy in the treatment of severe pulmonary arterial hypertension: Imatinib in pulmonary arterial hypertension, a randomized, efficacy study (IMPRES). NCT00902174. Bethesda, MD: National Institutes of Health; 2012.http://clinicaltrials.gov/ct2/show/ NCT00902174. Accessed August 1, 2012.
71. Hoeper M, Barst R, Galie N, et al. Imatinib in pulmonary arterial hypertension, a randomized efficacy study (IMPRES) [abstract]. Eur Respir J. 2011; 38 (suppl): A413.
72. McGonagle D, Tan AL, Madden J, et al. Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab. Rheumatology (Oxford). 2008; 47 (4): 552-553.
73. National Institutes of Health Clinical Center. A randomized, double-blind, placebo-controlled, phase II multicenter trial of a monoclonal antibody to CD20 (rituximab) for the treatment of systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH). NCT01086540. Bethesda, MD: National Institutes of Health; 2012.http://clinicaltrials.gov/ct2/show/record/ NCT01086540. Accessed December 12, 2012.
74. Shitrit D, Amital A, Peled N, et al. Lung transplantation in patients with scleroderma: case series, review of the literature, and criteria for transplantation. Clin Transplant. 2009; 23 (2): 178-183.
75. Schachna L, Medsger TA Jr, Dauber JH, et al. Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. Arthritis Rheum. 2006; 54 (12): 3954-3961.
76. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002; 40 (4): 780-788.
77. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002; 106 (12): 1477-1482.
78. Mathai SC, Puhan MA, Lam D, Wise RA. The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012; 186 (5): 428-433.
79. Gilbert C, Brown MC, Cappelleri JC, Carlsson M, McKenna SP. Estimating a minimally important difference in pulmonary arterial hypertension following treatment with sildenafil. Chest. 2009; 135 (1): 137-142.
80. Impens AJ, Wangkaew S, Seibold JR. The 6-minute walk test in scleroderma - how measuring everything measures nothing. Rheumatology (Oxford). 2008; 47 (suppl 5): v68-v69.
81. Buch MH, Denton CP, Furst DE, et al. Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test. Ann Rheum Dis. 2007; 66 (2): 169-173.
82. Garin MC, Highland KB, Silver RM, Strange C. Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma. J Rheumatol. 2009; 36 (2): 330-336.
83. Schoindre Y, Meune C, Dinh-Xuan AT, Avouac J, Kahan A, Allanore Y. Lack of specificity of the 6-minute walk test as an outcome measure for patients with systemic sclerosis. J Rheumatol. 2009; 36 (7): 1481-1485.
84. Mathai SC, Bueso M, Hummers LK, et al. Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension. Eur Respir J. 2010 ;35(1): 95-104.
85. Williams MH, Handler CE, Akram R, et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in sclerodermaassociated pulmonary arterial hypertension. Eur Heart J. 2006; 27 (12): 1485-1494.
86. Simeoni S, Lippi G, Puccetti A, et al. N-terminal pro-BNP in sclerodermic patients on bosentan therapy for PAH. Rheumatol Int. 2008; 28 (7): 657-660.
87. Mauritz GJ, Rizopoulos D, Groepenhoff H, et al. Usefulness of serial N-terminal pro-B-type natriuretic peptide measurements for determining prognosis in patients with pulmonary arterial hypertension. Am J Cardiol. 2011; 108 (11): 1645-1650.
88. Denton CP, Hachulla E. Risk factors associated with pulmonary arterial hypertension in patients with systemic sclerosis and implications for screening. Eur Respir Rev. 2011;20(122): 270-276.
89. Yeo TC, Dujardin KS, Tei C, Mahoney DW, McGoon MD, Seward JB. Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension. Am J Cardiol. 1998; 81 (9): 1157-1161.
90. Eysmann SB, Palevsky HI, Reichek N, Hackney K, Douglas PS. Two-dimensional and Doppler-echocardiographic and cardiac catheterization correlates of survival in primary pulmonary hypertension. Circulation. 1989; 80 (2): 353-360.
91. Forfia PR, Fisher MR, Mathai SC, et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med. 2006; 174 (9): 1034-1041.
92. Raymond RJ, Hinderliter AL, Willis PW, et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol. 2002; 39 (7): 1214-1219.
93. Mathai SC, Sibley CT, Forfia PR, et al. Tricuspid annular plane systolic excursion is a robust outcome measure in systemic sclerosis-associated pulmonary arterial hypertension. J Rheumatol. 2011; 38 (11): 2410-2418.
94. van Wolferen SA, Marcus JT, Boonstra A, et al. Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur Heart J. 2007; 28 (10): 1250-1257.
95. van Wolferen SA, van de Veerdonk MC, Mauritz GJ, et al. Clinically significant change in stroke volume in pulmonary hypertension. Chest. 2011; 139 (5): 1003-1009.
96. Vogel-Claussen J, Skrok J, Shehata ML, et al. Right and left ventricular myocardial perfusion reserves correlate with right ventricular function and pulmonary hemodynamics in patients with pulmonary arterial hypertension. Radiology. 2011; 258(1): 119-127.